SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: per strandberg who wrote (2728)11/11/1997 7:50:00 PM
From: JOHN W.  Read Replies (2) of 6136
 
Fortovase news was a positive vice negative event:
1)Royalties paid on Invirase in Europe to AGPH. Once again, the uninformed will be punished.

2) Fortovase/Viracept study is very promising.

3) The debate in Washington, to allow the Vaccine trial, even if the FDA goes out on a limb and goes forward with this very dangerous trial, would not even begin until the year 2000, with a vaccine not for another decade. C'mon guys.

4) consecutive 100% surprises in earnings, with the third in store.

5) Domestic sales alone growing at 100% and this stock is selling for 22 times FY99 earnings?

6) this weeks scrips were in excess of 8,000 for toatal just for the Retail side according to Co. I don't have the IMS data.

Caught the falling knife at 41 1/2. :-)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News